KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Profit After Tax (2016 - 2025)

Arbutus Biopharma's Profit After Tax history spans 13 years, with the latest figure at -$7.7 million for Q3 2025.

  • For Q3 2025, Profit After Tax rose 60.73% year-over-year to -$7.7 million; the TTM value through Sep 2025 reached -$42.3 million, up 44.88%, while the annual FY2024 figure was -$69.9 million, 4.02% up from the prior year.
  • Profit After Tax for Q3 2025 was -$7.7 million at Arbutus Biopharma, down from $2.5 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $2.5 million in Q2 2025 and bottomed at -$24.5 million in Q1 2025.
  • The 5-year median for Profit After Tax is -$17.9 million (2024), against an average of -$16.7 million.
  • The largest annual shift saw Profit After Tax crashed 37.62% in 2021 before it surged 112.74% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$21.3 million in 2021, then dropped by 2.87% to -$21.9 million in 2022, then rose by 11.95% to -$19.3 million in 2023, then surged by 35.11% to -$12.5 million in 2024, then surged by 38.22% to -$7.7 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Profit After Tax are -$7.7 million (Q3 2025), $2.5 million (Q2 2025), and -$24.5 million (Q1 2025).